You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMecamylamine
Accession NumberDB00657  (APRD00458)
TypeSmall Molecule
GroupsApproved
DescriptionA nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. [PubChem]
Structure
Thumb
Synonyms
Versamine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mecamylamine Hydrochloridetablet2.5 mg/1oralNexgen Pharma, Inc.2013-03-19Not applicableUs
Vecamyltablet2.5 mg/1oralManchester Pharmaceuticals2013-03-19Not applicableUs
Vecamyltablet2.5 mg/1oralTuring Pharmaceuticals2013-03-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
InversineTargacept
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mecamylamine hydrochloride
Thumb
  • InChI Key: PKVZBNCYEICAQP-UHFFFAOYNA-N
  • Monoisotopic Mass: 203.144077416
  • Average Mass: 203.752
DBSALT000652
Categories
UNII6EE945D3OK
CAS number60-40-2
WeightAverage: 167.2911
Monoisotopic: 167.167399677
Chemical FormulaC11H21N
InChI KeyInChIKey=IMYZQPCYWPFTAG-UHFFFAOYSA-N
InChI
InChI=1S/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3
IUPAC Name
N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
SMILES
CNC1(C)C2CCC(C2)C1(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassMonoterpenoids
Direct ParentBicyclic monoterpenoids
Alternative Parents
Substituents
  • Bicyclic monoterpenoid
  • Cyclohexylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension
PharmacodynamicsMecamylamine is a potent, oral antihypertensive agent and ganglion blocker, and is a secondary amine. Mecamylamine is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. Mecamylamine reduces blood pressure in both normotensive and hypertensive individuals. A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Mecamylamine crosses the blood-brain and placental barriers.
Mechanism of actionMecamylamine is a ganglionic blocker which prevents stimulation of postsynaptic receptors by acetylcholine released from presynaptic nerve endings. The hypotensive effect of Mecamylamine is attributed to reduction in sympathetic tone, vasodilation, and reduced cardiac output, and is primarily postural.
Related Articles
AbsorptionMecamylamine is almost completely absorbed from the gastrointestinal tract
Volume of distributionNot Available
Protein binding40%
MetabolismNot Available
Route of eliminationMecamylamine is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine crosses the blood-brain and placental barriers.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9566
Blood Brain Barrier+0.9771
Caco-2 permeable+0.611
P-glycoprotein substrateNon-substrate0.6815
P-glycoprotein inhibitor INon-inhibitor0.8271
P-glycoprotein inhibitor IINon-inhibitor0.889
Renal organic cation transporterNon-inhibitor0.7727
CYP450 2C9 substrateNon-substrate0.7864
CYP450 2D6 substrateNon-substrate0.7207
CYP450 3A4 substrateSubstrate0.5884
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9054
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7435
Ames testNon AMES toxic0.9315
CarcinogenicityNon-carcinogens0.8757
BiodegradationNot ready biodegradable0.6954
Rat acute toxicity2.3843 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9676
hERG inhibition (predictor II)Non-inhibitor0.8756
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Targacept inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral2.5 mg/1
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point249 with decompositionU.S. Patent 2,831,027.
boiling point72 °C at 4.00E+00 mm HgPhysProp
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.124 mg/mLALOGPS
logP3.13ALOGPS
logP2.37ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)10.88ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.83 m3·mol-1ChemAxon
Polarizability20.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 2,831,027.

General ReferencesNot Available
External Links
ATC CodesC02BB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINEThe risk or severity of adverse effects can be increased when 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE is combined with Mecamylamine.
1,10-PhenanthrolineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with 1,10-Phenanthroline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Mecamylamine.
AcebutololMecamylamine may increase the hypotensive activities of Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Acetazolamide.
AclidiniumAclidinium may increase the anticholinergic activities of Mecamylamine.
AclidiniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Aclidinium.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.
AlfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Mecamylamine.
AliskirenMecamylamine may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Alphacetylmethadol.
AlprenololMecamylamine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Mecamylamine can be increased when it is combined with Aluminum phosphate.
AmbenoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ambenonium.
AmbrisentanMecamylamine may increase the hypotensive activities of Ambrisentan.
AmifostineMecamylamine may increase the hypotensive activities of Amifostine.
AmikacinAmikacin may increase the neuromuscular blocking activities of Mecamylamine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mecamylamine.
AmlodipineAmlodipine may increase the hypotensive activities of Mecamylamine.
Ammonium chlorideThe serum concentration of Mecamylamine can be decreased when it is combined with Ammonium chloride.
AmobarbitalAmobarbital may increase the hypotensive activities of Mecamylamine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amyl Nitrite.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mecamylamine.
ApraclonidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Mecamylamine.
AtenololAtenolol may increase the hypotensive activities of Mecamylamine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mecamylamine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.
BarbitalBarbital may increase the hypotensive activities of Mecamylamine.
BenactyzineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Mecamylamine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mecamylamine.
BendroflumethiazideMecamylamine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Mecamylamine.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mecamylamine.
BepridilMecamylamine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Mecamylamine.
BethanidineBethanidine may increase the hypotensive activities of Mecamylamine.
BezitramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Bezitramide.
BimatoprostMecamylamine may increase the hypotensive activities of Bimatoprost.
BiperidenThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Biperiden.
Bismuth SubcitrateThe serum concentration of Mecamylamine can be increased when it is combined with Bismuth Subcitrate.
BisoprololBisoprolol may increase the hypotensive activities of Mecamylamine.
BosentanBosentan may increase the hypotensive activities of Mecamylamine.
Botulinum Toxin Type AMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BMecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.
BretyliumMecamylamine may increase the hypotensive activities of Bretylium.
BrimonidineMecamylamine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Mecamylamine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine.
BupranololMecamylamine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.
ButorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.
Calcium carbonateThe serum concentration of Mecamylamine can be increased when it is combined with Calcium carbonate.
CanagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.
CandesartanMecamylamine may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Mecamylamine.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Mecamylamine.
CaptoprilMecamylamine may increase the hypotensive activities of Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Carfentanil.
CaroxazoneCaroxazone may increase the hypotensive activities of Mecamylamine.
CarteololCarteolol may increase the hypotensive activities of Mecamylamine.
CarvedilolMecamylamine may increase the hypotensive activities of Carvedilol.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.
CeliprololMecamylamine may increase the hypotensive activities of Celiprolol.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.
ChlorothiazideMecamylamine may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Chlorphenoxamine.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.
ChlorthalidoneMecamylamine may increase the hypotensive activities of Chlorthalidone.
CilazaprilMecamylamine may increase the hypotensive activities of Cilazapril.
CimetropiumMecamylamine may increase the anticholinergic activities of Cimetropium.
ClevidipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.
ClonidineClonidine may increase the hypotensive activities of Mecamylamine.
CodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.
ColistimethateColistimethate may increase the neuromuscular blocking activities of Mecamylamine.
CoumaphosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Coumaphos.
CryptenamineMecamylamine may increase the hypotensive activities of Cryptenamine.
CyclopentolateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cyclopentolate.
CyclothiazideCyclothiazide may increase the hypotensive activities of Mecamylamine.
DapagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine.
DarunavirThe risk or severity of adverse effects can be increased when Darunavir is combined with Mecamylamine.
DaunorubicinDaunorubicin may increase the neuromuscular blocking activities of Mecamylamine.
DebrisoquinMecamylamine may increase the hypotensive activities of Debrisoquin.
DecamethoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Demecarium.
DeserpidineMecamylamine may increase the hypotensive activities of Deserpidine.
DesloratadineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.
DexetimideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dexetimide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine.
DextromoramideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dezocine.
DiazoxideThe risk or severity of adverse effects can be increased when Diazoxide is combined with Mecamylamine.
DiazoxideMecamylamine may increase the hypotensive activities of Diazoxide.
DichlorvosThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Dichlorvos.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine.
DicyclomineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dicyclomine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dihydromorphine.
DihydrostreptomycinDihydrostreptomycin may increase the neuromuscular blocking activities of Mecamylamine.
DiltiazemDiltiazem may increase the hypotensive activities of Mecamylamine.
DinutuximabThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Diphenoxylate.
DipyridamoleThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.
DonepezilThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Donepezil.
DorzolamideMecamylamine may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Mecamylamine.
DoxorubicinDoxorubicin may increase the neuromuscular blocking activities of Mecamylamine.
DPDPEThe risk or severity of adverse effects can be increased when Mecamylamine is combined with DPDPE.
DronabinolMecamylamine may increase the tachycardic activities of Dronabinol.
DuloxetineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.
EchothiophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Edrophonium.
EfonidipineMecamylamine may increase the hypotensive activities of Efonidipine.
EluxadolineMecamylamine may increase the constipating activities of Eluxadoline.
EmpagliflozinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Mecamylamine.
EnalaprilatMecamylamine may increase the hypotensive activities of Enalaprilat.
EpirubicinEpirubicin may increase the neuromuscular blocking activities of Mecamylamine.
EplerenoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Eplerenone.
EpoprostenolMecamylamine may increase the hypotensive activities of Epoprostenol.
EprosartanMecamylamine may increase the hypotensive activities of Eprosartan.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mecamylamine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mecamylamine.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Mecamylamine.
EthylmorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etorphine.
FelodipineMecamylamine may increase the hypotensive activities of Felodipine.
FenoldopamMecamylamine may increase the hypotensive activities of Fenoldopam.
FentanylThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fentanyl.
FenthionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Fesoterodine.
FosinoprilFosinopril may increase the hypotensive activities of Mecamylamine.
FramycetinFramycetin may increase the neuromuscular blocking activities of Mecamylamine.
FurazolidoneFurazolidone may increase the hypotensive activities of Mecamylamine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mecamylamine.
GalantamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mecamylamine.
GentamicinGentamicin may increase the neuromuscular blocking activities of Mecamylamine.
Ginkgo bilobaThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Mecamylamine.
GlycopyrroniumMecamylamine may increase the anticholinergic activities of Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Mecamylamine.
GuanadrelGuanadrel may increase the hypotensive activities of Mecamylamine.
GuanethidineMecamylamine may increase the hypotensive activities of Guanethidine.
GuanfacineMecamylamine may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Heroin.
HexamethoniumMecamylamine may increase the hypotensive activities of Hexamethonium.
HexamethylenetetramineThe serum concentration of Mecamylamine can be decreased when it is combined with Hexamethylenetetramine.
HexobarbitalHexobarbital may increase the hypotensive activities of Mecamylamine.
HomatropineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Huperzine A.
HydracarbazineHydracarbazine may increase the hypotensive activities of Mecamylamine.
HydralazineMecamylamine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mecamylamine.
HydrochlorothiazideMecamylamine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.
HydroflumethiazideMecamylamine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydromorphone.
Hygromycin BHygromycin B may increase the neuromuscular blocking activities of Mecamylamine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mecamylamine.
IdarubicinIdarubicin may increase the neuromuscular blocking activities of Mecamylamine.
IloprostIloprost may increase the hypotensive activities of Mecamylamine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.
IndapamideMecamylamine may increase the hypotensive activities of Indapamide.
IndenololMecamylamine may increase the hypotensive activities of Indenolol.
IndoraminMecamylamine may increase the hypotensive activities of Indoramin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.
IproclozideIproclozide may increase the hypotensive activities of Mecamylamine.
IproniazidIproniazid may increase the hypotensive activities of Mecamylamine.
IrbesartanMecamylamine may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Mecamylamine.
IsoflurophateThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Mecamylamine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Mecamylamine.
KanamycinKanamycin may increase the neuromuscular blocking activities of Mecamylamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Ketobemidone.
LabetalolLabetalol may increase the hypotensive activities of Mecamylamine.
LacidipineMecamylamine may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Mecamylamine.
LercanidipineLercanidipine may increase the hypotensive activities of Mecamylamine.
LevobunololThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levobunolol.
LevodopaMecamylamine may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Levorphanol.
LisinoprilMecamylamine may increase the hypotensive activities of Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Lofentanil.
LofexidineMecamylamine may increase the hypotensive activities of Lofexidine.
LosartanMecamylamine may increase the hypotensive activities of Losartan.
MacitentanMecamylamine may increase the hypotensive activities of Macitentan.
MafenideThe risk or severity of adverse effects can be increased when Mafenide is combined with Mecamylamine.
MagaldrateThe serum concentration of Mecamylamine can be increased when it is combined with Magaldrate.
Magnesium carbonateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium oxide.
Magnesium TrisilicateThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.
MalathionThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Malathion.
ManidipineMecamylamine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.
MebanazineMebanazine may increase the hypotensive activities of Mecamylamine.
MefloquineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methantheline.
MethazolamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Mecamylamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Mecamylamine.
MethyldopaMecamylamine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Mecamylamine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Mecamylamine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mecamylamine.
MetipranololMecamylamine may increase the hypotensive activities of Metipranolol.
MetixeneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Metixene.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.
MetolazoneMecamylamine may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Mecamylamine.
MetrizamideMetrizamide may increase the neuromuscular blocking activities of Mecamylamine.
MianserinMianserin may increase the anticholinergic activities of Mecamylamine.
MibefradilMecamylamine may increase the hypotensive activities of Mibefradil.
MinaprineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Minaprine.
MinoxidilMinoxidil may increase the hypotensive activities of Mecamylamine.
MirabegronThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.
MoclobemideMoclobemide may increase the hypotensive activities of Mecamylamine.
MoexiprilMecamylamine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Mecamylamine.
MorphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Morphine.
MoxonidineMecamylamine may increase the hypotensive activities of Moxonidine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with N-butylscopolammonium bromide.
NabiloneMecamylamine may increase the tachycardic activities of Nabilone.
NadololMecamylamine may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nalbuphine.
NebivololMecamylamine may increase the hypotensive activities of Nebivolol.
NeomycinNeomycin may increase the neuromuscular blocking activities of Mecamylamine.
NeostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nesiritide.
NetilmicinNetilmicin may increase the neuromuscular blocking activities of Mecamylamine.
NialamideNialamide may increase the hypotensive activities of Mecamylamine.
NicardipineNicardipine may increase the hypotensive activities of Mecamylamine.
NicorandilNicorandil may increase the hypotensive activities of Mecamylamine.
NifedipineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nifedipine.
NiguldipineMecamylamine may increase the hypotensive activities of Niguldipine.
NilvadipineMecamylamine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Mecamylamine.
NisoldipineNisoldipine may increase the hypotensive activities of Mecamylamine.
NitrendipineMecamylamine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Mecamylamine.
NormethadoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Mecamylamine is combined with NVA237.
ObinutuzumabMecamylamine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Mecamylamine.
OlmesartanOlmesartan may increase the hypotensive activities of Mecamylamine.
OmapatrilatMecamylamine may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Orphenadrine.
OxprenololMecamylamine may increase the hypotensive activities of Oxprenolol.
OxybutyninThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mecamylamine.
PancuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.
PapaverineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.
PargylineMecamylamine may increase the hypotensive activities of Pargyline.
ParomomycinParomomycin may increase the neuromuscular blocking activities of Mecamylamine.
PenbutololMecamylamine may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the hypotensive activities of Mecamylamine.
PentoliniumMecamylamine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Mecamylamine.
PerindoprilMecamylamine may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Mecamylamine.
PheniprazinePheniprazine may increase the hypotensive activities of Mecamylamine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Mecamylamine.
PhenoxybenzamineMecamylamine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Mecamylamine.
PhentolamineMecamylamine may increase the hypotensive activities of Phentolamine.
PhysostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.
PinacidilMecamylamine may increase the hypotensive activities of Pinacidil.
PindololMecamylamine may increase the hypotensive activities of Pindolol.
PipecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.
PirlindolePirlindole may increase the hypotensive activities of Mecamylamine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Mecamylamine.
PlicamycinPlicamycin may increase the neuromuscular blocking activities of Mecamylamine.
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Mecamylamine.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Mecamylamine.
PolythiazideMecamylamine may increase the hypotensive activities of Polythiazide.
Potassium ChlorideMecamylamine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Mecamylamine.
PrazosinPrazosin may increase the hypotensive activities of Mecamylamine.
PrimidonePrimidone may increase the hypotensive activities of Mecamylamine.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mecamylamine.
PropanthelineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Propantheline.
PropranololPropranolol may increase the hypotensive activities of Mecamylamine.
PuromycinPuromycin may increase the neuromuscular blocking activities of Mecamylamine.
PyridostigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine.
QuetiapineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.
QuinaprilMecamylamine may increase the hypotensive activities of Quinapril.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Mecamylamine.
QuinidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Mecamylamine.
RamiprilRamipril may increase the hypotensive activities of Mecamylamine.
RamosetronMecamylamine may increase the constipating activities of Ramosetron.
RasagilineRasagiline may increase the hypotensive activities of Mecamylamine.
RemifentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.
RemikirenRemikiren may increase the hypotensive activities of Mecamylamine.
RescinnamineMecamylamine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Mecamylamine.
RibostamycinRibostamycin may increase the neuromuscular blocking activities of Mecamylamine.
RiociguatMecamylamine may increase the hypotensive activities of Riociguat.
RisperidoneMecamylamine may increase the hypotensive activities of Risperidone.
RituximabMecamylamine may increase the hypotensive activities of Rituximab.
RivastigmineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Rivastigmine.
RosuvastatinThe risk or severity of adverse effects can be increased when Rosuvastatin is combined with Mecamylamine.
SafrazineSafrazine may increase the hypotensive activities of Mecamylamine.
SaprisartanMecamylamine may increase the hypotensive activities of Saprisartan.
ScopolamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the hypotensive activities of Mecamylamine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.
SelegilineSelegiline may increase the hypotensive activities of Mecamylamine.
SelexipagMecamylamine may increase the hypotensive activities of Selexipag.
SildenafilThe risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine.
Silver sulfadiazineThe risk or severity of adverse effects can be increased when Silver sulfadiazine is combined with Mecamylamine.
SimeprevirThe risk or severity of adverse effects can be increased when Simeprevir is combined with Mecamylamine.
SitaxentanMecamylamine may increase the hypotensive activities of Sitaxentan.
SolifenacinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Solifenacin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.
SpectinomycinSpectinomycin may increase the neuromuscular blocking activities of Mecamylamine.
SpiraprilMecamylamine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.
StreptomycinStreptomycin may increase the neuromuscular blocking activities of Mecamylamine.
StreptozocinStreptozocin may increase the neuromuscular blocking activities of Mecamylamine.
SufentanilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.
SulfacetamideThe risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine.
SulfachlorpyridazineThe risk or severity of adverse effects can be increased when Sulfachlorpyridazine is combined with Mecamylamine.
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Mecamylamine.
SulfadimethoxineThe risk or severity of adverse effects can be increased when Sulfadimethoxine is combined with Mecamylamine.
SulfadoxineThe risk or severity of adverse effects can be increased when Sulfadoxine is combined with Mecamylamine.
SulfamerazineThe risk or severity of adverse effects can be increased when Sulfamerazine is combined with Mecamylamine.
SulfameterThe risk or severity of adverse effects can be increased when Sulfameter is combined with Mecamylamine.
SulfamethazineThe risk or severity of adverse effects can be increased when Sulfamethazine is combined with Mecamylamine.
SulfamethizoleThe risk or severity of adverse effects can be increased when Sulfamethizole is combined with Mecamylamine.
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Mecamylamine.
SulfametopyrazineThe risk or severity of adverse effects can be increased when Sulfametopyrazine is combined with Mecamylamine.
SulfamoxoleThe risk or severity of adverse effects can be increased when Sulfamoxole is combined with Mecamylamine.
SulfanilamideThe risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine.
SulfaphenazoleThe risk or severity of adverse effects can be increased when Sulfaphenazole is combined with Mecamylamine.
SulfapyridineThe risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine.
SulfaquinoxalineThe risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Mecamylamine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.
SulfathiazoleThe risk or severity of adverse effects can be increased when Sulfathiazole is combined with Mecamylamine.
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Mecamylamine.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine.
TacrineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tacrine.
TadalafilTadalafil may increase the antihypertensive activities of Mecamylamine.
TapentadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.
TelmisartanMecamylamine may increase the hypotensive activities of Telmisartan.
TemocaprilMecamylamine may increase the hypotensive activities of Temocapril.
TerazosinThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.
TerlipressinMecamylamine may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Mecamylamine.
ThiopentalThiopental may increase the hypotensive activities of Mecamylamine.
TiboloneMecamylamine may increase the hypotensive activities of Tibolone.
TicrynafenMecamylamine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Mecamylamine.
TiotropiumMecamylamine may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Mecamylamine.
TizanidineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tizanidine.
TobramycinTobramycin may increase the neuromuscular blocking activities of Mecamylamine.
TolazolineMecamylamine may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Mecamylamine.
TolterodineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Mecamylamine.
TramadolThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.
TrandolaprilTrandolapril may increase the hypotensive activities of Mecamylamine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Mecamylamine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Mecamylamine.
TravoprostTravoprost may increase the hypotensive activities of Mecamylamine.
TreprostinilTreprostinil may increase the hypotensive activities of Mecamylamine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.
TrichlorfonThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mecamylamine.
TrichlormethiazideMecamylamine may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine.
TrimazosinMecamylamine may increase the hypotensive activities of Trimazosin.
TrimethaphanMecamylamine may increase the hypotensive activities of Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mecamylamine.
TubocurarineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Mecamylamine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Mecamylamine.
UmeclidiniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Umeclidinium.
UnoprostoneMecamylamine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Mecamylamine.
VardenafilVardenafil may increase the antihypertensive activities of Mecamylamine.
VecuroniumThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.
VerapamilThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.
XylometazolineMecamylamine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Mecamylamine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA: Mecamylamine, dihydro-beta-erythroidine, and dextromethorphan block conditioned responding evoked by the conditional stimulus effects of nicotine. Pharmacol Biochem Behav. 2009 Dec;94(2):319-28. doi: 10.1016/j.pbb.2009.09.012. Epub 2009 Sep 22. [PubMed:19778551 ]
  5. Shytle RD, Penny E, Silver AA, Goldman J, Sanberg PR: Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. [PubMed:12080428 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23